Table 4.
Results of other studies investigating the serological response to COVID-19 vaccination in psoriasis patients.
| Reference | Total number of psoriasis patients and healthy controls finally investigated | Therapies | Antibody response in psoriasis patients under therapy with biologics N (%) |
Antibody response in psoriasis patients under therapy with MTX as main or co-medication N (%) |
|---|---|---|---|---|
| Mahil et al., Lancet Rheumatol. (49) | 64 patients and 15 controls | MTX n=14 TNF-α inhibitor n=18 IL-17 inhibitor n=13 IL-23 inhibitor n=19 |
50 (100.0) following the second dose of BNT162b2 vaccination |
14 (100.0) following the second dose after BNT162b2 vaccination |
| Marovt et al., Clin Exp Dermatol. (50) | 32 patients and 22 controls | TNF-α inhibitor n=7 IL-12/23 inhibitor n=11 IL-17 inhibitor n=6 IL-23 inhibitor n=8 |
32 (100.0) following the second dose of BNT162b2 vaccination |
N/A |
| Graceffa et al., Front Med (Lausanne). (51) | 45 patients and 45 controls | TNF-α inhibitor + MTX n=4 TNF-α inhibitor n=17 IL-12/23 inhibitor n=7 IL-17 inhibitor n= 5 IL-23 inhibitor n=12 |
44 (97.8)1
following the second dose of BNT162b2 vaccination |
3 (75)1
following the second dose of BNT162b2 vaccination |
| Piros et al., Dermatol Ther. (52) | 102 patients and 55 controls | TNF-α inhibitor n=57 IL-12/23 inhibitor n=28 IL-17 inhibitor n=16 IL-23 inhibitor n=1 |
102 (100.0) following the second dose of BNT162b2 or mRNA-1273 vaccination |
N/A |
1: One female patient on combination therapy (infliximab + methotrexate) did not respond to the double dose of vaccine.
IL, Interleukin; MTX, Methotrexate; N/A, Not applicable.